CannTrust investing approx. CAD $6 million for 20% stake in Australian company Cannatrek. Continue reading CannTrust stakes claim in Australia
Health Canada approval for next phase of vaporized cannabinoid drug clinical trial.
Clinical trial to start and finish by year end Continue reading Health Canada green light for next phase of first clinical trial with vaporized cannabinoid drug.
Tilray will be part of clinical trial to study possibility that THC and CBD could shrink tumours and increase survival times in brain cancer. Continue reading Tilray and brain-cancer clinical trial in Spain
The University of Colorado School of Medicine is conducting a phase two clinical trial to determine if CBD can reduce symptoms of Parkinson’s disease
Continue reading Phase 2 clinical trial: CBD for Parkinsons
Aurora’s CanniMed cannabis-oil products to be used in a clinical trial for Parkinson’s disease.
The study will determine the safety and tolerability of three different formulations of the cannabis oil for pain in Parkinson’s patients. Continue reading Clinical trial: Aurora cannabis oil for Parkinson’s
A new phase two clinical trial sponsored by University of California Center for Medicinal Cannabis Research is examining the effects of vaporized-cannabis to treat HIV-related neuropathic pain. Continue reading New clinical trial: Vaping for chronic nerve pain in HIV
Tetra’s PPP001 is currently in Phase 3, with the end goal being a DIN,” says Aphria CEO.
“Enormous opportunity” for relationship with Tetra, as supplier and shareholder. Continue reading Aphria CEO shares info on Tetra Bio Pharma during Q1 2019 results
Tetra Bio-Pharma and clinical research partner Santé Cannabis conduct first-ever and most exhaustive clinical trial to evaluate safety and efficacy of different doses and ratios of cannabis oils versus placebo for (non-cancer) chronic pain. On track for completion later this fall.
Continue reading Tetra Bio-Pharma first-past-the-post on clinical trial for chronic pain
TetraBioPharma is quickly advancing plans to commercialize its #cannabis-based drug and specially designed vaporizer to treat fibromyalgia after getting approval from the Independent Ethics Board.
Continue reading Tetra Bio-Pharma fibromyalgia treatment one step closer
Fibromyalgia patients using cannabis saw dramatic improvement and astonished physicians w/ comments like “This is a miraculous treatment” & “I returned to same person I was before” Continue reading “Miraculous.” Cannabis dramatically improved fibromyalgia symptoms.
New cannabis-supply agreements for Aurora’s subsidiary MedReleaf now gives the company a presence from Canada’s west coast to the most eastern part of North America all the way up to North of 60. Continue reading Aurora goes east and north-of-60 with new agreements
Columbia University researchers hoping high-CBD, low-THC strain of cannabis will be well tolerated in patients with aggressive form of brain cancer, #glioblastoma and decrease radiation-induced toxicities and nausea and other symptoms. Continue reading Reducing toxic effects of chemo-radiation in brain-cancer patients
Maricann today announced its launch of new product line that will feature four strains under the brand name Kiwi.
Continue reading Maricann launches new product line
Researchers have discovered that cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite caused by inflammatory bowel disease.
Several clinical trials are planned or underway to assess the effectiveness of THC and CBD in treating these conditions, such a Crohn’s and colitis. Continue reading Can THC treat inflammatory bowel disease?
Heath Canada decision to reclassify, to a Phase Two medical device, the @TetraBioPharma inhalation pipe for cannabis medication means that patients suffering cancer pain may soon be able to claim the cost through their private and public insurance plans. Continue reading Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.
At University of Colorado, approximately 60 people will participate in a clinical trial with hopes that CBD will relieve some of the troubling symptoms of Parkinson’s Disease.
Continue reading Parkinson’s clinical trial in Colorado
A University of Utah clinical trial is evaluating the effectiveness two different combinations of THC and CBD as treatment for chronic pain and life functioning. Continue reading Clinical trial: THC and CBD for chronic pain
@Tilray and McMaster to conduct clinical trial for anxiety disorders. Continue reading Tilray clinical trial for anxiety disorders
A new study published in the medical journal Depression and Anxiety found that one-third of the approximately 1.1 million U.S. military spouses suffer one or more psychiatric conditions. Led by New York University School of Medicine’s Dr. Maria Steenkamp, the … Continue reading New study: Military spouses are hurting too
Pity the pessimistic investor who thought that shorting Aurora was smart. Continue reading Aurora short positions not turning out so well
A heart clinic in Mexico is planning a clinical trial led by a Professor of Medicine at Cornell University to determine safety of CBD in patients who’ve survived heart failure. Continue reading First clinical trial to test CBD for heart failure
GW Pharmaceuticals is conducting a clinical trial on the effectiveness of its #CBD drug in treating tremors in #Parkinson’s Disease.
The company said it expects to complete the study in June 2019. Continue reading GW Pharma clinical trial for Parkinsons
First drug (Epidiolex) containing purified substance derived from marijuana was approved by U.S. FDA: We’ll continue to support rigorous scientific research on potential medical uses of marijuana-derived products,” said FDA Commissioner Scott .Gottlieb Continue reading GW Pharma makes history as FDA approves first-ever cannabis drug
Aphria and Canadian bio-technology company Rapid Dose Therapeutics have signed an MOU that Aphria will have exclusive global preferred rights to produce, distribute and sell QuickStrip(TM) products for cannabis markets around the world, once a definitive agreement is signed between the two companies in the near future. Continue reading Aphria signs deal; exclusive global partner for QuickStrip
New York University School of Medicine will conduct the first-ever study to test the hypothesis that oral CBD will reduce alcohol consumption in individuals suffering both PTSD and Alcohol Use Disorder. Continue reading First of its kind study to look at CBD for alcohol use & PTSD
Cannabis extracts control pain, reduce muscle paralysis and stiffness, and even protect the brain from further injury in MS patients, according to a new study out of Rome. Continue reading Mounting evidence that cannabis is good medicine for MS
Children with a severe form of #epilepsy experienced fewer seizures and a better quality of life, according to the first study of its kind.
@Tilray CBD oil was used in the phase 2 clinical trial. Continue reading Tilray’s CBD/THC mixture found safe kids with drug-resistant epilepsy
Drug company earning multi-millions on MS med containing only 2 ingredients – THC and CBD ready to launch epilepsy drug this fall & now racing to develop CBD drugs for schizophrenia, #autism & other hard-to treat diseases. Continue reading GWPH studying CBD for schizophrenia & other hard-to-treat diseases
First CBD and THC company in Italy planned as @MaricannInc partners with Italian producer. Centre of excellence for cannabis products also in the works. #cannabis Continue reading First CBD & THC company in Italy; Maricann partners with Italian producer
Link btwn cannabis and glaucoma known for 25 yrs. Continue reading Seeing in the dark; better night vision after drinking cannabis “tea”
We need to acknowledge the giants of cannabis research and pay homage to their immeasurable contributions. Continue reading The pioneers of cannabis research. Where would we be without them?
Study: Less emphysema for cannabis smokers but more bouts with bronchitis in heavy smokers. Continue reading Cannabis smokers get less emphysema and do better on breathing tests
An international research project led by McGill University will examine the potential of CanniMed CBD oil to treat chronic pain, and related anxiety and depression. Continue reading Aurora supporting study of CBD as treatment for pain, depression, anxiety
Scientific evidence of cannabinoids as safe, effective treatment for schizophrenia is so powerful, compelling and widespread that it’s almost indisputable.
Why did it take us so long to get here? Continue reading The shame of schizophrenia is ours; CBD suspected as good medicine for years
CBD has beneficial effects in patients with schizophrenia and, may represent a new class of treatment for the disorder,”s ays are American psychiatrists.
Continue reading CBD quells psychosis in schizophrenia; “beneficial effects” says American Journal of Psychiatry.
Australian researchers reviewed 31 scientific studies that showed the distinct, specific effects of THC and CBD on mental health and brain function. Continue reading Cannabis contradiction: THC does this, CBD does that….
Brand new research shows that if the body’s Anandamide levels can be prevented from falling, PTSD treatment may be more effective. Anandamide is the human cannabinoid that’s sometimes called the bliss molecule. The study shows that putting stress on the brain … Continue reading Fatty acid hurts PTSD healing
The discovery of a new molecule that’s similar to the Anandamide molecule is creating a buzz. We already know that the cannabinoids CBD and THC are powerful anti-inflammatories. Now a new cannabinoid – PEA – has been found to benefit … Continue reading New discovery: cannabinoid that reduces inflammation in the intestines.
A third Cannabinoid Receptor has been identified. CB3-is the stomach and intestines.
Study shows overactive endo-cannabinoid system causes desire to eat while reducing ability to burn off calories. Continue reading Why do we get the munchies and how can we lose weight?
A new study suggests that “extremely low doses of THC may provide a safe and effective treatment for cognitive decline in aging humans.”
Continue reading THC: Anti-aging elixir?
An “endocannabinoid deficiency” can lead to disease. Continue reading Waking up the cannabinoid system in your body
Experimental research shows that cannabinoid receptors are increased in areas where lesions have formed in the brain. Continue reading Treating brain disease
Feeling light-headed or dizzy after marijuana use is one of the first signs that your cardiovascular system is in distress. Fainting is another. Continue reading Can inhaling cannabis be a heart hazard?
Stanley Brothers has created Charlotte’s Web Holdings and is seeking regulatory approval in Canada for a proposed initial public offering of its common shares.
It is anticipated that the Offering Price will be between C$6.00 and C$7.00 per Common Share.
Continue reading Charlotte’s Web Holdings IPO in the works
The potential healing properties of cannabis are becoming increasingly evident. Hundreds of thousands of studies have been done in search of better treatment for diseases involving just about every system and organ in the body.
Continue reading Fifty years of scientific research
Studies out of Isreal, Italy, Spain, China, Germany and other European countries say that genetic deficiencies of the endocannabinoid system may be at play in severe headaches. Continue reading Migraines and cannabis
With an FDA nod to GW Pharma, the CBD-based anti-seizure medication Epilodex will be on the market before the end of 2018. First-of-its kind medical trial seizures in children with a rare, life-threatening type of epilepsy.
#cannabis Continue reading GW Pharma to market CBD child-epilepsy drug
more targeted treatments may help alleviate pain without dangerous side effects such as addiction.
Continue reading Targeting pain
The potential healing properties of cannabis extracts are becoming increasingly evident as scientists seek new and better treatment for diseases involving just about every system and organ in the body. Studies and clinical trials in the hundreds of thousands have been conducted or are underway. Continue reading What scientists know
Approximately 136 US military veterans in the San Diego area will participate in a phase 2 clinical trial that will test the effects of CBD on Post-Traumatic-Stress Disorder. Continue reading Clinical trial: CBD for veterans with PTSD
Inhaling cannabis makes for easier breathing, because it dilates – or opens up – the airways in the lungs, according to a 1973 study published in New England Journal of Medicine.
GW Pharmaceuticals’ research and development for the therapeutic use of cannabinoids dates back at least two decades.
Continue reading Patents granted to GW Pharmaceuticals for therapeutic use of cannabinoids
Aphria’s Australian-based partner Althea granted Manufacture Licence by the Australian Government’s Office of Drug Control.